Warning Letter — Ezra Holdco LLC dba Ezra
The FDA issued a warning letter to Ezra Holdco LLC (dba Ezra) following an evaluation by the Center for Drug Evaluation and Research (CDER). While the source does not detail the specific violations, it confirms the issuance of formal enforcement action against the entity.
This affects Ezra Holdco LLC and its subsidiary operations, as well as regulatory and compliance departments within firms offering screening services or health-related technology.
The involvement of the Center for Drug Evaluation and Research (CDER) suggests that the FDA’s concerns may involve the intersection of diagnostic services and therapeutic claims or the use of unapproved products. This letter indicates a high level of regulatory scrutiny regarding how health screening companies market their services and whether those services require specific FDA clearances that may currently be lacking.
Review all marketing materials and web content to ensure that claims regarding disease screening or diagnostic capabilities match the cleared indications for use. Audit internal clearance documentation to verify that any software or AI-driven tools utilized in patient screening have received appropriate 510(k) clearance or PMA approval.
FDA Warning Letter issued to: Ezra Holdco LLC dba Ezra. 06/08/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ezra-holdco-llc-dba-ezra-730995-06082026
Open in openFDA / FDA.gov